The relationship of Growth differentiation factor-15 with renal damage and dyslipidemia in non-albuminuric and albuminuric Type-2 Diabetes Mellitus
Article Sidebar
Main Article Content
Abstract
Objective: Aim of this study is to investigate the correlation of Growth differentiation factor-15 with renal damage and dyslipidemia in Type-2 Diabetes Mellitus.
Material and Method: The study was conducted prospectively with patients diagnosed with Type-2 Diabetes Mellitus. Two groups were formed as non-albuminuric (n:47) and albuminuric (n:24). Age, gender, Growth differentiation factor-15, glycemic index, lipid panel, glomerular filtration rate, complete blood count, urine albumin/creatin and urine protein/creatin of the groups were compared, and their correlations were examined.
Results: Growth differentiation factor-15, age, and hemoglobin A1c were found to be higher in the albuminuric group, and hemoglobin and hematocrit levels were found to be lower. A positive correlation of Growth differentiation factor-15 with spot urine albumin/creatin and protein/creatin was observed in the albuminuric group. In the non-albuminuric group, positive correlation was observed with Triglyceride and a negative correlation with high-density lipoprotein cholesterol. Negative correlation of Growth differentiation factor-15 glomerular filtration rate was detected in all participants.
Conclusions: Growth differentiation factor-15 has been found positively associated with albuminuria and high triglyceride levels in Type-2 Diabetes Mellitus. It is negatively correlated with glomerular filtration rate and high-density lipoprotein cholesterol. It is strongly associated with renal damage and dyslipidemia.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2022-06-09
Published 2022-06-10
References
Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev. 2013 ;24(4):373-84. DOI: https://doi.org/10.1016/j.cytogfr.2013.05.003
Wollert KC, Kempf T, Wallentin L. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clin Chem. 2017 ;63(1):140-151. DOI: https://doi.org/10.1373/clinchem.2016.255174
Shin MY, Kim JM, Kang YE, Kim MK, Joung KH, Lee JH, et al. Association between Growth Differentiation Factor 15 (GDF15) and Cardiovascular Risk in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. J Korean Med Sci. 2016 ;31(9):1413-8. DOI: https://doi.org/10.3346/jkms.2016.31.9.1413
Adela R, Banerjee SK. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective. J Diabetes Res. 2015;2015:490842. DOI: https://doi.org/10.1155/2015/490842
Dostálová I, Roubícek T, Bártlová M, Mráz M, Lacinová Z, Haluzíková D, et al. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol. 2009 ;161(3):397-404. DOI: https://doi.org/10.1530/EJE-09-0417
Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P, et al.Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology. 2009 ;150(4):1688-96.
Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886-99. DOI: https://doi.org/10.1007/s00125-015-3525-8
Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003 ;46(6):733-49. DOI: https://doi.org/10.1007/s00125-003-1111-y
Tziomalos K, Athyros VG, Karagiannis A, Kolovou GD, Mikhailidis DP. Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr Drug Targets. 2009 ;10(4):320-7. DOI: https://doi.org/10.2174/138945009787846425
Desmedt S, Desmedt V, De Vos L, Delanghe JR, Speeckaert R, Speeckaert MM. Growth differentiation factor 15: A novel biomarker with high clinical potential. Crit Rev Clin Lab Sci. 2019 ;56(5):333-350. DOI: https://doi.org/10.1080/10408363.2019.1615034
Kempf T, Guba-Quint A, Torgerson J, Magnone MC, Haefliger C, Bobadilla M,et al. Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese non-diabetic individuals: results from the XENDOS trial. Eur J Endocrinol. 2012 ;167(5):671-8. DOI: https://doi.org/10.1530/EJE-12-0466
Carballo-Casla A, García-Esquinas E, Buño-Soto A, Struijk EA, López-García E, et al. Metabolic syndrome and Growth Differentiation Factor 15 in older adults. Geroscience. 2022 ;44(2):867-880. DOI: https://doi.org/10.1007/s11357-021-00370-w
Carlsson AC, Nowak C, Lind L, Östgren CJ, Nyström FH, Sundström J, et al. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J Med Sci. 2020 ;125(1):37-43. DOI: https://doi.org/10.1080/03009734.2019.1696430
Chung JO, Chung MY, Park SY, Cho DH, Chung DJ. Relationship between plasma growth differentiation factor-15 level and estimated glomerular filtration rate in type 2 diabetes patients with and without albuminuria. J Diabetes Complications. 2021 ;35(4):107849. DOI: https://doi.org/10.1016/j.jdiacomp.2021.107849
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 5;150(9):604-12. DOI: https://doi.org/10.7326/0003-4819-150-9-200905050-00006
Umanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum 2018. Am J Kidney Dis. 2018 ;71(6):884-895 DOI: https://doi.org/10.1053/j.ajkd.2017.10.026
Hsiao EC, Koniaris LG, Zimmers-Koniaris T, Sebald SM, Huynh TV, Lee SJ. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol. 2000 ;20(10):3742-51. DOI: https://doi.org/10.1128/MCB.20.10.3742-3751.2000
Simonson MS, Tiktin M, Debanne SM, Rahman M, Berger B, Hricik D,et al. The renal transcriptome of db/db mice identifies putative urinary biomarker proteins in patients with type 2 diabetes: a pilot study. Am J Physiol Renal Physiol. 2012 1;302(7):F820-9. DOI: https://doi.org/10.1152/ajprenal.00424.2011
Agarwal RG, Khokhar M, Purohit P, Modi A, Bajpai NK, Bohra GK,et al. A clinical and in-silico study of MicroRNA-21 and growth differentiation factor-15 expression in pre-diabetes, type 2 diabetes and diabetic nephropathy. Minerva Endocrinol (Torino). 2022 Feb 1. Epub ahead of print. DOI: https://doi.org/10.23736/S2724-6507.22.03646-6
Simm A, Nass N, Bartling B, Hofmann B, Silber RE, Navarrete Santos A. Potential biomarkers of ageing. Biol Chem. 2008 ;389(3):257-65. DOI: https://doi.org/10.1515/BC.2008.034
Bilson J, Scorletti E, Bindels LB, Afolabi PR, Targher G, Calder PC, et al. Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD. Nutr Diabetes. 2021 18;11(1):32. DOI: https://doi.org/10.1038/s41387-021-00170-3
Li H, Gao F, Xue Y, Qian Y. [Value of plasma growth differentiation factor-15 in diagnosis and evaluation of type 2 diabetic nephropathy]. Nan Fang Yi Ke Da Xue Xue Bao. 2014 ;34(3):387-90. Chinese
Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2015 9;5(1):49-56.
Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011 ;17(5):581-8. DOI: https://doi.org/10.1038/nm.2354
Ito K, Yokota S, Watanabe M, Inoue Y, Takahashi K, Himuro N,et al. Anemia in Diabetic Patients Reflects Severe Tubulointerstitial Injury and Aids in Clinically Predicting a Diagnosis of Diabetic Nephropathy. Intern Med. 2021;60(9):1349-1357. DOI: https://doi.org/10.2169/internalmedicine.5455-20
El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, et al. Kidney Early Evaluation Program. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005 ;67(4):1483-8. DOI: https://doi.org/10.1111/j.1523-1755.2005.00226.x
Rabelink TJ, de Zeeuw D. The glycocalyx--linking albuminuria with renal and cardiovascular disease. Nat Rev Nephrol. 2015 ;11(11):667-76. DOI: https://doi.org/10.1038/nrneph.2015.162
Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P, et al. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology. 2009 ;150(4):1688-96. DOI: https://doi.org/10.1210/en.2008-0952
Shimano M, Ouchi N, Walsh K. Cardiokines: recent progress in elucidating the cardiac secretome. Circulation. 2012;20;126(21):e327-32. DOI: https://doi.org/10.1161/CIRCULATIONAHA.112.150656
Ho JE, Mahajan A, Chen MH, Larson MG, McCabe EL, Ghorbani A,et al. Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem. 2012 ;58(11):1582-91. DOI: https://doi.org/10.1373/clinchem.2012.190322
Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016 ;26(4):364-73. DOI: https://doi.org/10.1016/j.tcm.2015.10.004
Bermúdez B, López S, Pacheco YM, Villar J, Muriana FJ, Hoheisel JD,et al. Influence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary artery. Cardiovasc Res. 2008;15;79(2):294-303. DOI: https://doi.org/10.1093/cvr/cvn082
Xu X, Li Z, Gao W. Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside. Biomarkers. 2011;16(6):466-75. DOI: https://doi.org/10.3109/1354750X.2011.580006
Kim JM, Back MK, Yi HS, Joung KH, Kim HJ, Ku BJ. Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia. Diabetes Metab J. 2016 ;40(1):70-8. DOI: https://doi.org/10.4093/dmj.2016.40.1.70